Melbourne Law School High Court Blog

By Legal Eagle

Melbourne Law School has just set up a new High Court Blog (Opinions on High) with yours truly as one of the editors. I won’t be writing regular detailed posts in the way that I have traditionally done for Skepticlawyer, although I did write this one on malicious prosecution for the new blog. The other editors and I will do small news posts on matters relating to High Court cases.

As for everything else, I am still trying to finish off my textbook, and I have been severely ill with asthma and in hospital, but now all is better. That’s why you haven’t seen me about much. *Waves and disappears back into the never never*

7 Comments

  1. Posted August 1, 2013 at 9:57 am | Permalink

    Or, ‘Exits stage left’. Best wishes for the new venture, and especially for your health. You do know how much we all take good health for granted.

  2. Posted August 1, 2013 at 12:02 pm | Permalink

    Echo Don’s sentiments entirely!

  3. Mel
    Posted August 1, 2013 at 4:40 pm | Permalink

    Very sorry to hear of your health problems, LE. I felt like my chest was being crushed in a vice when I had pneumonia. Awful. I hope you stay healthy and hubby and the kids are well.

    Hugs and kisses.

    Steve.

  4. John H.
    Posted August 3, 2013 at 10:10 am | Permalink

    LE,

    A new drug for asthma is available and might be worth thinking about. It is a 5-LOX inhibitor and this class of drugs is also showing some promise in treating some cancers because 5-LOX is an important mediator of arachidonic acid derived inflammatory mediators.

    Note the side effects though but still worth thinking about.

    Ann Pharmacother. 1996 Jul-Aug;30(7-8):858-64.
    Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
    Wenzel SE, Kamada AK.
    Source
    Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.

    Abstract
    OBJECTIVE:
    To introduce and review zileuton, an orally active 5-lipoxygenase inhibitor that represents the first of a new class of medications to be used in the treatment of asthma.

    DATA SOURCES:
    A MEDLINE search (from 1966 to December 1995) was performed to identify pertinent English-language literature.

    STUDY SELECTION:
    Basic science studies on the pharmacokinetics of zileuton, its pathophysiologic effects on asthma, and clinical efficacy trials were reviewed.

    DATA EXTRACTION:
    Clinical trials were emphasized. Studies from ex vivo or animal models of pharmacologic and pharmacodynamic effects were considered for review where no in vivo human data were available.

    DATA SYNTHESIS:
    Zileuton has shown the ability to attenuate induced bronchospasm, produce some degree of bronchodilation, and provide antiinflammatory or steroid-sparing effects with both single doses (800 mg) and chronic treatment (400 and 600 mg qid). Zileuton has been studied in patients requiring daily inhaled beta-adrenergic agonist treatment; however, data from pediatric populations and comparisons with other asthma medications are limited at this time. Adverse effects include dyspepsia and elevated liver enzymes (incidence approximately 3%). One case of jaundice has been reported among the more than 5000 patients treated with zileuton. There is also some concern for drug interactions with hepatically cleared medications, such as theophylline.

    CONCLUSIONS:
    Zileuton represents the first drug of a new treatment category for asthma, the 5-lipoxygenase inhibitors. Some people with asthma may receive considerable benefit, but as it is an entirely new drug entity, zileuton’s final place in the hierarchy of asthma medications remains to be determined.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*